**NeoReviews™ Editorial Board Disclosures**

The American Academy of Pediatrics (AAP), Policy on Disclosure of Financial Relationships and Resolution of Conflicts of Interest for AAP CME Activities, is designed to ensure quality, objective, balanced, and scientifically rigorous AAP CME activities by identifying and resolving all potential conflicts of interest before the confirmation of service of those in a position to influence and/or control the content of commercial activities discussed in CME activities. Commercial interest is the commercial interest of the CME provider.

All individuals in a position to influence and/or control the content of a CME activity are required to disclose to the AAP and subsequently to learners that the individual either has no relevant financial relationships or any financial relationships with the manufacturer(s) of any commercial products(s) and/or provider(s) of commercial services discussed in CME activities. Commercial interest is defined as any entry producing, marketing, reselling or distributing health-care goods or services consumed by, or used on, patients. Each of the editorial board members, reviewers, question writers, and staff has disclosed, if applicable, that the CME content he/she edits/writes/revise may include discussion/references to generic pharmaceuticals, off-label pharmaceutical use, investigational uses, brand names, and manufacturers.

None of the editors, board members, reviewers, question writers, or staff has any relevant financial relationships to disclose unless noted below. The AAP has taken steps to resolve any potential conflicts of interest.

**Disclosures**

- Ivan Hand, MD, FAAP, disclosed that he participates in the Abbott Nutrition and MedImmune speaker bureau.
- Josef Neo, MD, FAAP, disclosed that he serves as a consultant to Abbott Nutrition, Life Sciences Office, Environ and NeoLique, and that he has a research grant, serves as a consultant and on the advisory board of MedImmune.
- William Truog, MD, FAAP, disclosed that he participates in a pilot clinical research study for ONY Inc, and participates in the Trial of Late Surfactant (to prevent BPD) of the National Heart, Blood and Lung Institute.


<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: <a href="http://neoreviews.aappublications.org/content/13/8.citation">http://neoreviews.aappublications.org/content/13/8.citation</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="https://shop.aap.org/licensing-permissions/">https://shop.aap.org/licensing-permissions/</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: <a href="http://classic.neoreviews.aappublications.org/content/reprints">http://classic.neoreviews.aappublications.org/content/reprints</a></td>
</tr>
</tbody>
</table>